The cancer which had become painful and ulcerated was diagnosed and removed by physicians at Barnes-Jewish Hospital.
The patient's diagnosis with Marjolin's ulcer an invasive and potentially deadly squamous cell cancer surprised physicians.
This type of cancer most often is identified in patients with a previous history of skin cancers
This model supported cancer development so strongly that some mice developed invasive squamous cell skin cancers similar to the patient's tumor said lead author Shadmehr Demehri MD Phd a dermatologist
and molecules are most supportive of cancer formation. If you're allergic to something the first thing to do is to avoid it
Similar to metal implants some dental restoration materials and tattoo inks contain substances associated with allergic reactions and cancers on the skin or in the mouth.
"For example, Tian noted, the plasmonic paper can be used to detect target molecules that serve as indicators for diseases such as kidney cancer."
#Gene that drives aggressive brain cancer found by new computational approach Using an innovative algorithm that analyzes gene regulatory and signaling networks,
Columbia University Medical center (CUMC) researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer.
the Clyde and Helen Wu Professor of Chemical Biology (in Biomedical Informatics and the Institute for Cancer Genetics), chair of the Department of Systems Biology,
Dr. Califano and his colleagues used high-power computer models to demonstrate that certain types of cancer have conserved highly"master regulators"--genes
which"walks"backward from the master regulators to find the genetic events that drive cancer."
and mutational profile data of more than 250 patients collected by the Cancer Genome Atlas consortium.
C/EBPD, had already been identified by the labs of Dr. Califano and of Antonio Iavarone, MD, professor of neurology and of pathology & cell biology (in the Institute for Cancer Genetics),
which had never been tied to this or any other form of cancer. In subsequent laboratory studies, the researchers reactivated the defective KLHL9 gene in aggressive glioblastoma cells,
are directly responsible for driving this cancer subtype. DIGGIT may be applicable to other complex diseases. In further studies by the Califano team, the algorithm identified 35 genes as drivers of breast cancer.
confirming that the algorithm is capable of capturing driver mutations in other types of cancer.
tissue that detect prostate cancer Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients,
The study sets the stage for the development of more-sensitive and specific noninvasive tests for prostate cancer than those currently available,
According to the American Cancer Society, prostate cancer is the second most common type of cancer in American men (behind skin cancer
and the second-leading cause of cancer death in men (after lung cancer. In 2014, more than 230,000 new cases of prostate cancer will be diagnosed.
One in seven American men will get prostate cancer during his lifetime, and one in 36 will die from it.
Since most men with prostate cancer have indolent (nonaggressive) disease for which conservative therapy or surveillance would be appropriate treatment,
the clinical challenge is not only how to identify those with prostate cancer, but also how to distinguish those who would benefit from surgical
or other aggressive treatment from those who would not. Today, prostate cancer is detected primarily and monitored by testing for high concentrations of prostate specific-antigen antigen (PSA) in blood samples.
High PSA levels are followed often by a biopsy to confirm the presence of cancer, and whether it's slow growing or aggressive."
"While elevated PSA can be an alert to a lethal cancer, it can also detect less aggressive cancers that may never do said any harm
Vipul Patel, M d.,medical director of the Global Robotics Institute at Florida Hospital in Orlando."
"Moreover, only 25 percent of men with raised PSA levels that have a biopsy actually have prostate cancer.
Prostate cancer needs to be screened for; we just need to find a better marker.""The researchers believe that they have identified a group of RNA molecules--known as long noncoding RNAS (lncrnas)--that hold the potential for serving as better prognostic markers for prostate cancer. lncrnas are non-coding RNA
molecules that until recently were dismissed by scientists as nonfunctional noise in the genome. Now, lncrnas are thought to regulate normal cellular development
and are reported increasingly as contributing to a range of diseases, including cancer.""We have identified a set of lncrnas that appear to have an important role in prostate cancer diagnostics,
"said Ranjan J. Perera, Ph d.,associate professor and scientific director of Analytical Genomics and Bioinformatics at Sanford-Burnham's Lake Nona campus in Orlando."
"The findings advance our understanding of the role of lncrnas in cancer biology and, importantly, broaden the opportunity to use lncrnas as biomarkers to detect prostate cancer."
"The study profiled the lncrnas in three distinct groups:(1) human prostate cancer cell lines and normal prostate epithelial cells,(2) prostate adenocarcinoma tissue samples and matched normal tissue samples,(3) urine samples
from patients with prostate cancer or benign prostate hypoplasia, and normal healthy individuals. In each case, the lncrnas were elevated in prostate cancer patient samples,
but not in patients with benign prostate hypoplasia or normal healthy individuals. One advantage of lncrnas is that the molecules can be detected in urine samples,
which are more easily available than blood tests. One lncrna, PCA3, was commercialized recently as a urine test to identify which men suspected of having prostate cancer should undergo repeat prostate biopsy.
However discrepancies have been found to exist between PCA3 levels and clinicopathologic features, said Dr. Perera.
but not all of the study samples, suggesting that reliance on a single biomarker may be insufficient for prostate cancer detection,
"There is a tremendous unmet clinical need for better noninvasive screening tools for early detection of prostate cancer to reduce the overtreatment and morbidity of this disease,"added Dr. Patel."
whether lncrnas are expressed differentially in prostate cancer by measuring total RNA from prostate cancer cell lines
lncrna expression was compared in pooled prostate cancer tissue samples and matched normal tissues from 10 frozen biopsy specimens.
An additional set of 18 prostate cancer tissue samples was analyzed by qpcr and five lncrnas were found to be significantly higher in prostate tumor tissues compared with matched normal tissues.
Urine was collected from 13 prostate cancer patients and 14 healthy controls. All six lncrnas were found to be regulated significantly up in the urine samples from the prostate cancer patients compared with normal patient controls
while there were no differences between normal and benign prostatic hyperplasia patient samples. In other studies focused particularly on SPRY4-IT1.
In a collaboration among the Jaffe Food Allergy Institute The Mindich Child Health and Development Institute Immunology Institute and Tisch Cancer Institute at The Mount sinai Hospital researchers exposed mice
#Colorectal cancer: New clues for early detection Researchers at the University of Luxembourg have identified potential new ways to test for the first signs of one of the most deadly types of cancer:
colorectal cancer. They have found new biomarkers: molecules whose increased presence or absence in tissue suggests the development of tumorous cells.
These indicators could help detect colorectal cancer at an early stage predict its severity or even offer new treatments.
Colorectal cancer is still one of the most frequent and deadliest cancers worldwide. But diagnosed in time it can be cured in 9 out of 10 cases said Professor Serge Haan from the Life science Research Unit at the University of Luxembourg.
Thus it is highly important to identify more sensitive and specific markers to improve early diagnosis as well as therapeutic strategies.
Serge Haan and Dr. Elisabeth Letellier studied over 800 detailed results of tissue-analysis of both patients with various stages of colorectal cancer and healthy individuals.
Further analysis also revealed that this protein could even give an early prediction of the cancer's severity.
There is increasing evidence that the loss of SOCS proteins plays a role in many cancers as this induce uncontrolled cell growth and tumour development.
These findings have been published in The british Journal of Cancer. The research team included several Luxembourg biomedical research institutions:
This study was financed by the Luxembourg Cancer Foundation. Further work is needed now to expand on these findings before they can be used clinically l
#New lab-on-a-chip could revolutionize early diagnosis of cancer Scientists have been laboring to detect cancer and a host of other diseases in people using promising new biomarkers called exosomes.
Indeed Popular Science magazine named exosome-based cancer diagnostics one of the 20 breakthroughs that will shape the world this year.
Exosomes could lead to less invasive earlier detection of cancer and sharply boost patients'odds of survival.
Now Zeng and colleagues from the University of Kansas Medical center and KU Cancer Center have published just a breakthrough paper in the Royal Society of Chemistry journal describing their invention of a miniaturized biomedical testing device for exosomes.
Zeng and his fellow researchers have developed the lab-on-a-chip for early detection of lung cancer--the number-one cancer killer in the U s. Today lung cancer is detected mostly with an invasive biopsy after tumors are larger than 3 centimeters in diameter and even
Unlike some cancer types such as breast or colon cancer no widely accepted screening tool has been available for detecting early-stage lung cancers.
Tumor biopsy is often impossible for early cancer diagnosis as the developing tumor is too small to see by the current imaging tools.
Beyond lung cancer Zeng said the lab-on-a-chip could be used to detect a range of potentially deadly forms of cancer.
Our technique provides a general platform to detecting tumor-derived exosomes for cancer diagnosis he said.
In addition to lung cancer we've also tested for ovarian cancer in this work. In theory it should be applicable to other types of cancer.
Our long-term goal is to translate this technology into clinical investigation of the pathological implication of exosomes in tumor development.
Cells have adapted further autophagy for other purposes as well including recycling dysfunctional components immune response to pathogen invasion surveillance against cancer
by supporting the altered metabolism of growing cancers. With let-7 revealed to be a master regulator of metabolism helping to modulate anabolic growth (the creation of new molecules in cells) with catabolic destruction (the breakdown of molecules in cells) researchers say the overall picture
Biomarker reveals cancer cause The expression of the protein CLIP2*provides information on whether a papillary thyroid carcinoma was induced by radiation
With this discovery, scientists from the Helmholtz Zentrum München have identified a new biomarker for the diagnosis of the cancer cause.
Radiation marker CLIP2 allows distinction of cancer cause and risk assessment"CLIP2 serves as a radiation marker
and to evaluate the risk of thyroid cancer after exposure to high level radiation, for instance, following a radiation accident,"reports Heß.
In addition to diabetes and lung diseases, this also includes cancer. The objective of the Helmholtz Zentrum München is the rapid further development of the results of basic research
#Non-coding half of human genome unlocked with novel sequencing technique An obscure swatch of human DNA once thought to be nothing more than biological trash may actually offer a treasure trove of insight into complex genetic-related diseases such as cancer
--and cancer Scientists reveal the structure of one of the most important and complicated proteins in cell division--a fundamental process in life
and the development of cancer--in research published in Nature. Images of the gigantic protein in unprecedented detail will transform scientists'understanding of exactly how cells copy their chromosomes
A team from The Institute of Cancer Research London and the Medical Research Council Laboratory of Molecular biology in Cambridge produced the first detailed images of the anaphase-promoting complex (APC/C). The APC/C
Discovering its structure could ultimately lead to new treatments for cancer which hijacks the normal process of cell division to make thousands of copies of harmful cancer cells.
In the study which was funded by Cancer Research UK the researchers reconstituted human APC/C
Dr David Barford who led the study as Professor of Molecular biology at The Institute of Cancer Research London before taking up a new position at the Medical Research Council Laboratory of Molecular biology in Cambridge said:
Professor Paul Workman Interim Chief executive of The Institute of Cancer Research London said: The fantastic insights into molecular structure provided by this study are a vivid illustration of the critical role played by fundamental cell biology in cancer research.
The new study is a major step forward in our understanding of cell division. When this process goes awry it is a critical difference that separates cancer cells from their healthy counterparts.
Understanding exactly how cancer cells divide inappropriately is crucial to the discovery of innovative cancer treatments to improve outcomes for cancer patients.
Dr Kat Arney Science Information Manager at Cancer Research UK said Figuring out how the fundamental molecular'nuts and bolts'of cells work is vital
The above story is provided based on materials by Cancer Research UK. Note: Materials may be edited for content and length.
hold great promise for treating cancer and other diseases. However, several inefficiencies have limited their translation to the clinic
says Gregory Szeto, a postdoc at MIT Koch Institute for Integrative Cancer Research and the paper lead author.
This research was funded by the Kathy and Curt Marble Cancer Research Fund through the Koch Institute Frontier Research Program, the National Cancer Institute, the National Institute of General medicine Sciences
In addition to the development of effective new drugs and diagnosis methods for diseases including cancer, it could potentially lead to new reenpesticides using pheromones tailored specifically to attract pollinators
and is affiliated with UCLA Jonsson Comprehensive Cancer Center and a member of the Broad Stem Cell Research center.
for Integrative Cancer Research. Eliana Martins Lima, of the Federal University of Goiás, is the other co-author.
A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases.
The multidisciplinary team drawing on their expertise in genetics, cancer, computational biology, pharmacology, and other disciplines also tested the response of tumor cells with specific mutations to anticancer drugs.
which leads to activation of the same cancer-causing pathway, said Dr. Michael Krauthammer, associate professor of pathology and the study corresponding author.
said Ruth Halaban, senior research scientist in dermatology, a member of Yale Cancer Center, and lead author of the study. oss of NF1 requires more accompanying changes to make a tumor,
and can be applied to personalized cancer treatment. By testing the response of the melanoma samples to two cancer drugs,
The study was supported by the Yale SPORE in Skin cancer, funded by the National Cancer Institute, U s. National institutes of health, under award number 1 P50 CA121974;
and the Yale Comprehensive Cancer Center. Publication: Michael Krauthammer, et al, xome sequencing identifies recurrent mutations in NF1 and RASOPATHY genes in sun-exposed melanomas, Nature Genetics, 2015;
But while those guard against the long-term risks of thyroid cancer linked with chronic radiation exposure
As science links these variants to disease risk, the idea has been that genotypes could predict your chance of getting cancer or heart disease
Treating cancer is one area where RNAI s particular advantages are expected to shine. Conventional chemotherapy affects more than just the target cancer cells it also hurts healthy tissue
which could make cancer treatments far more effective. Lab work like this is far from fruition but if it maintains its momentum the drugs currently in clinical trials could represent just a small portion of the benefits of the discovery of RNAI i
The U k. project will focus on people with cancer, as well as adults and children with rare diseases.
That is because for cancer patients Genomics England intends to obtain the sequence of both their inherited DNA as well as that of their cancers.
was linked to a 41 percent increase in the detection of invasive cancers as well as a 15 percent drop in the recall rate,
if they miss a cancer because they weren using tomosynthesis, they could end up being sued by someone who said,
Such 2-D mammograms can create superimposed shadows that look like cancer, and they sometimes fail to detect cancer lesions behind normal tissue.
In tomosynthesis approved by the FDA in 2011, a series of x-ray images are taken in an arc across the breast,
in fact, a lot of what we know about cancer genetics comes from research on our fungal friends.
#Machine that unboils eggs now being used to improve cancer treatment A machine that can be used to uncook eggs is now being used to dramatically improve the effectiveness of a cancer treatment.
Using the invention on carboplatin a common cancer treatment drug, used against ovarian and lung cancers has boosted the potency by almost five times.
"Raston told ABC News. A machine that can be used to uncook eggs is now being used to dramatically improve the effectiveness of a cancer treatment.
Using the invention on carboplatin a common cancer treatment drug, used against ovarian and lung cancers has boosted the potency by almost five times.
#In a first, cold sore virus used to fight cancer cells Scientists have the first proof that a"brand new"way of combating cancer,
Specialists at the NHS Royal Marsden Hospital and the Institute of Cancer Research (ICR) confirmed that melanoma skin cancer patients treated with a modified herpes virus (the virus that causes cold sores) had improved survival-a world first.
randomised trial of a so-called oncolytic virus to show success. Cancer scientists predict it will be the first of many in the coming years-adding a new weapon to our arsenal of cancer treatments.
Other forms of immunotherapy-the stimulation of the body's own immune system to fight cancer-using antibodies rather viruses,
Viral immunotherapies are also being investigated for use against advanced head and neck cancers, bladder cancers and liver cancers.
Kevin Harrington, UK trial leader and professor of biological cancer therapies at the ICR and an honorary consultant at the Royal Marsden, said he hoped the treatment could be available for routine use within a year in many countries
"We hope this is the first of a wave of indications for these sorts of cancer fighting agents that we will see coming through in the next decade or so."
and kill human cells that can make them such promising cancer treatments.""The study, which is published in the Journal of Clinical Oncology, included 436 patients, all of
is that they work by stimulating an immune response against cancer, "he said.""The field has moved very quickly clinically.
"Dr Hayley Frend, science information manager at Cancer Research UK, said the potential for viruses in future cancer treatments was"exciting"."
Melanoma is the fifth most common cancer in the UK, and is becoming more widespread
if the cancer-indicated by the appearance of a new mole on the skin-is caught early.
Scientists have the first proof that a"brand new"way of combating cancer, using genetically modified viruses to attack tumour cells,
Specialists at the NHS Royal Marsden Hospital and the Institute of Cancer Research (ICR) confirmed that melanoma skin cancer patients treated with a modified herpes virus (the virus that causes cold sores) had improved survival-a world first.
randomised trial of a so-called oncolytic virus to show success. Cancer scientists predict it will be the first of many in the coming years-adding a new weapon to our arsenal of cancer treatments.
Other forms of immunotherapy-the stimulation of the body's own immune system to fight cancer-using antibodies rather viruses,
Viral immunotherapies are also being investigated for use against advanced head and neck cancers, bladder cancers and liver cancers.
Kevin Harrington, UK trial leader and professor of biological cancer therapies at the ICR and an honorary consultant at the Royal Marsden, said he hoped the treatment could be available for routine use within a year in many countries
"We hope this is the first of a wave of indications for these sorts of cancer fighting agents that we will see coming through in the next decade or so."
and kill human cells that can make them such promising cancer treatments.""The study, which is published in the Journal of Clinical Oncology, included 436 patients, all of
is that they work by stimulating an immune response against cancer, "he said.""The field has moved very quickly clinically.
"Dr Hayley Frend, science information manager at Cancer Research UK, said the potential for viruses in future cancer treatments was"exciting"."
Melanoma is the fifth most common cancer in the UK, and is becoming more widespread
if the cancer-indicated by the appearance of a new mole on the skin-is caught early.
#Tata doctors find way to cut oral cancer risk Tata Memorial Hospital, the cancer hub in Parel, announced a breakthrough on Tuesday that could
not only reduce the risk of death for oral cancer patients by 36 %but also prevent recurrence of the disease by 55%.
%The innovation is an'extra cut'-a dissection in medical parlance-along the neck to detect
if the patient's cancer had spread from his/her oral cavity to the neck. The cut would be a prophylaxis-a preventive medicine-against aggressive cancer forms
and prevent the need for chemotherapy or radiation. The findings were announced by Tata Memorial Centre's Dr Anil D'Cruz at an ongoing meeting of American Society of Clinical Oncology at Chicago on May 31.
because India carries the highest burden of oral cancer in the world, with around 1 lakh new patients detected every year.
It is the most common cancer among Indian men and third most common among Indian women.
whether the cancer has progressed beyond to the neck region. This is especially in the early stages of oral cancer.''
''At present, patients may choose to not undergo neck dissection and wait until some cancerous bulge-basically,
whether or not early stage oral cancer patients should undergo a neck dissection. On one hand, the dissection is a delicate operation
they may be at the risk of not diagnosing the cancer's complete spread early enough.
#Tata docs find way to cut oral cancer risk Tata Memorial Hospital, the cancer hub in Parel, announced a breakthrough on Tuesday that could
not only reduce the risk of death for oral cancer patients by 36 %but also prevent recurrence of the disease by 55%.
%The innovation is an'extra cut'-a dissection in medical parlance-along the neck to detect
if the patient's cancer had spread from his/her oral cavity to the neck. The cut would be a prophylaxis-a preventive medicine-against aggressive cancer forms
and prevent the need for chemotherapy or radiation. The findings were announced by Tata Memorial Centre's Dr Anil D'Cruz at an ongoing meeting of American Society of Clinical Oncology at Chicago on May 31.
because India carries the highest burden of oral cancer in the world, with around 1 lakh new patients detected every year.
It is the most common cancer among Indian men and third most common among Indian women.
whether the cancer has progressed beyond to the neck region. This is especially in the early stages of oral cancer.''
''At present, patients may choose to not undergo neck dissection and wait until some cancerous bulge-basically,
whether or not early stage oral cancer patients should undergo a neck dissection. On one hand, the dissection is a delicate operation
they may be at the risk of not diagnosing the cancer's complete spread early enough.
#New sensor to detect cancer, HIV, hepatitis Researchers have developed a highly sensitive nanomechanical sensor that can detect cancerous tumours as well as viral disease markers for HIV,
#New sensor to detect cancer, HIV Researchers have developed a highly sensitive nanomechanical sensor that can detect cancerous tumours as well as viral disease markers for HIV,
The breakthrough, described in the journal Human Reproduction, gives hope to thousands of young cancer victims who face treatments such as chemotherapy which can damage the ovaries
The breakthrough, described in the journal Human Reproduction, gives hope to thousands of young cancer victims who face treatments such as chemotherapy which can damage the ovaries
a breakthrough that could potentially save the careers of top athletes besides cure untreatable injuries caused from accidents and surgeries due to cancer."
those who have had surgery for cancer, or sufferers of amyotrophic lateral sclerosis (ALS).""This technology could cure (recently retired Chinese hurdler) Liu Xiang's injury,
"This invention will allow us to detect anything we might be interested in, bacterial contamination or perhaps a protein molecule that is a cancer marker.
#New sensor chip to detect prostate cancer early Researchers have developed a smart sensor chip that can detect prostate cancer more accurately
will help improve the process of early stage prostate cancer diagnosis, researchers said. Glycoprotein molecules play an essential role in our immune response, because of
which they are useful clinical biomarkers for detecting prostate cancer and other diseases. The team of chemical engineers and chemists at the University of Birmingham, created a sensor chip with synthetic receptors along a 2d surface to identify specific
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011